Oragenics, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone fourth-quarter filing. Oragenics is a development-stage biotechnology company focused on AG013 for oral mucositis and OG716, an investigational antibiotic for C. difficile infection. It sold its consumer probiotics business in June 2016.
Financial results and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Continuing-operations revenue | $0 | $0 |
| R&D expense | $4.75 million | $8.73 million |
| General and administrative expense | $3.79 million | $3.05 million |
| Loss from continuing operations | $8.50 million | $11.84 million |
| Net loss | $7.01 million | $11.71 million |
| Operating cash used | $7.08 million | $5.19 million |
| Cash and cash equivalents at year-end | $4.08 million | $5.08 million |
| Working capital surplus at year-end | $2.88 million | $4.59 million |
- Reported net loss improved year over year partly because of a $1.45 million gain on the sale of the probiotics business. The continuing-operations loss was $8.50 million.
- R&D expense fell 45.6%, chiefly because 2015 included a $5.0 million Intrexon technology access fee. R&D spending on collaboration work increased in 2016; G&A rose 24.3%.
- Probiotics revenue of $464,048 in 2016 and $1.18 million in 2015 is reported within discontinued operations; the continuing-operations revenue line was zero in both years. The business was sold for $1.7 million, with contingent consideration of up to $2.0 million based on sales over ten years.
- Fourth-quarter 2016 net loss was $2.67 million, versus $2.22 million in fourth-quarter 2015. Q4 R&D expense increased 32.5% year over year and G&A increased 9.0%.
- Year-end liabilities included $1.28 million of accounts payable and accrued expenses and $66,377 of short-term notes payable. A $2.0 million note related to the 2016 private placement was paid in full in January 2017.
Business developments, outlook and risks
- AG013: The company reported prior Phase 1b results in 25 cancer patients: treatment was described as safe and well tolerated, with a 35% reduction in duration of ulcerative oral mucositis versus placebo. The FDA granted Fast Track designation in November 2016. Management expected to update the IND and begin a Phase 2 study in the U.S. and Europe in 2017, subject to adequate financing.
- OG716: Selected in 2016 as the second-generation lantibiotic candidate for C. difficile. Promising animal-model results were reported against vancomycin, but the candidate had not entered human trials. Management expected a pre-IND meeting in Q2 2017 and targeted an IND filing in the second half of 2017, contingent on capital availability.
- Funding and going concern: The auditor’s report raises substantial doubt about the company’s ability to continue as a going concern. Management said available cash would support operations as then structured only through May 2017. Additional financing was uncommitted and not assured; without it, planned development could be delayed, reduced or discontinued.
- Financing and dilution: A June 2016 private placement issued 9.05 million shares and raised approximately $4.67 million. Further equity financing could dilute shareholders. At year-end, Intrexon and the Koski Family Limited Partnership beneficially owned approximately 31.5% and 34.5%, respectively, according to the filing.
- Collaboration obligations: The company bears significant development funding responsibilities under its Intrexon agreements. The Oral Mucositis agreement includes milestone payments totaling as much as $32 million per product, payable in cash or, in specified circumstances and at the company’s option, shares; none had been achieved by year-end. Lantibiotic milestones may also result in share issuances or cash payments.
- Other risks and unusual items: OG716 and AG013 remain unapproved and depend on further clinical, regulatory and manufacturing success. The company cited financing, product development, manufacturing scale-up, clinical enrollment, regulatory approval, intellectual-property protection and competition as material risks. NYSE MKT had accepted a plan for the company to regain listing compliance by November 10, 2017, subject to progress reviews.
Important facts for investors to verify
- Subsequent financing, cash balances and actual operating runway after the May 2017 estimate.
- Whether the expected AG013 Phase 2 and OG716 regulatory milestones occurred, and their funding and trial status.
- Cash-flow and expense trends, including Intrexon collaboration costs and any unpaid amounts.
- Terms and collection of the probiotics sale’s contingent consideration, and any continuing transition-service payments.
- NYSE MKT listing-plan progress, potential dilution and the effect of Intrexon milestone obligations.